Single User License: Cancer Genome Sequencing Market Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 – 2022 USD 4315.5     Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.co m sales@transparencymarketresearch. com Flat 10% Discount!! Free Customization as per your requirement You will get Custom Report at Syndicated Report price Report will be delivered with in 15-20 working days Request Sample Buy Now REPORT DESCRIPTION Over the last few years, the genomic era of cancer studies is developing at a rapid pace fueled by the emergence of next-generation sequencing technology rendering exquisite resolution and sensitivity. Frequent alterations in their gross chromosomal structure by means of amplification, deletion and inversion of their chromosomal structure forms a characteristic feature of cancer genome. These gene alterations or modifications ultimately lead to cancer onset and progression. Browse Full Report with TOC @ http://www.transparencymarketresearch.com/cancer-genomesequencing-market.html Additionally, the gene sequencing for cancer has several advantages over traditional approaches which include the ability to perform complete gene sequencing in single test including the detecting copy number alterations, translocations, and exome-wide base substitutions in all related cancer cells. The reduction in the cost associated with whole genome sequencing and overall time required to perform these sequencing has drastically reduced in last couple of years. A study published by TheHuffingtonPost.com, Inc. in 2013 illustrated that five years ago expenses for performing whole genome sequencing were in millions of dollars which currently can be performed solely for few thousand dollars. Numerous technological advancements have significantly contributed in advancing the research studies pertaining to cancer diagnosis and treatment. Despite this the recombinant DNA cloning is still in its infancy and is yet not competent enough in unraveling the full complexity of the human cell. In June 2014, a new genome sequencing test developed at Memorial Sloan Kettering known as MSK-IMPACT made cancer analysis far more comprehensive and can be used on any type of solid tumor, irrespective of its location in the human body. According to the scientists of Memorial Sloan Kettering, cancer identification and its predisposition can benefit patients, health practitioners and eventually help in reducing the morbidity and mortality with respect to cancer. A study by Johns Hopkins scientists published in April 2015 illustrated that in last few years several hospitals and companies have collaborated to sequence patient’s tumor in an attempt to personalize therapy for cancer treatment. In addition to selecting personalized therapies for patients with cancer, sequencing the normal tissue genome can also increase the overall understanding of cancer, including finding reasons for cancer predisposition due to germline genome changes. Regulations pertaining to personalized cancer sequencing are primarily governed by the accreditation of the laboratories performing the sequencing services and analysis, and also the usage of FDA approved tests for conducting these tests. Drivers to the cancer genome sequencing encompass comprehensive view of whole genome, ability to majority of mutations, and eliminating the need for having any prior knowledge about the patient history and current disease status. Such potential growth attributors are likely to boost the demand for gene sequencing-based personalized cancer treatment in the near future. High procedural cost and time consuming interpretation of large datasets are among the key restraints to the market. An alternative to the whole genome sequencing is the targeted gene sequencing method that is comparative less costly, with easy results interpretation and high sensitivity for rare clones. Geographically, the market is studied for four regions; North America, Europe, Asia Pacific and Rest of the World. North America market includes the United States and Canada which form the major revenue contributors owing to increasing inclination towards gene therapy-based cancer treatment. The region is followed by Europe which has also initiated several genome-based studies in cancer. An analysis conducted by Genomics England Ltd. in 2014, revealed that the U.K. is set to become the world leader in ground breaking genetic research into cancer and rare diseases post a grant of USD 473.3 million by Prime Minister of U.K. Asia Pacific and Rest of the World are still in nascent stage owing to the need for high initial investment on laboratory set-up and conducting research activity. However the APAC market is expected to grow in the forthcoming years due to availability of skilled and scientific-based manpower, strength in information technology and its growing economy. Some of the major companies operating in cancer genome sequencing market include Illumina, Inc., Beckman Coulter Genomics, SeqWright, BGI Americas Corporation, Pacific Biosciences, Ambry Genetics, and Foundation Medicine. This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include • North America • Asia Pacific • Europe • Middle East and Africa • Latin America This report provides comprehensive analysis of • Market growth drivers • Factors limiting market growth • Current market trends • Market structure • Market projections for upcoming years This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. Inquiry Before Buying: http://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=4619 Latest Press Release Reports: http://www.transparencymarketresearch.com/press-releases.htm Latest Articles Reports: http://www.transparencymarketresearch.com/articles.htm Read More Reports on Biotechnology Market: http://www.transparencymarketresearch.com/biotechnology-market-reports-18.html About Us Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge. Contact: Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/

Over the last few years, the genomic era of cancer studies is developing at a rapid pace fueled by the emergence of next-generation sequencing technology rendering exquisite resolution and sensitivity. Frequent alterations in their gross chromosomal structure by means of amplification, deletion and inversion of their chromosomal structure forms a characteristic feature of cancer genome. These gene alterations or modifications ultimately lead to cancer onset and progression. Browse Full Report with TOC @ http://www.transparencymarketresearch.com/cancer-genome-sequencing-market.html